These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1918474)

  • 1. Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
    Joly P; Lampert A; Thomine E; Lauret P
    J Am Acad Dermatol; 1991 Aug; 25(2 Pt 1):332-3. PubMed ID: 1918474
    [No Abstract]   [Full Text] [Related]  

  • 2. [Scleroderma-like syndrome with bullous morphea during treatment with 5-hydroxytryptophan, carbidopa and flunitrazepam].
    Lampert A; Joly P; Thomine E; Ortoli JC; Lauret P
    Ann Dermatol Venereol; 1992; 119(3):209-11. PubMed ID: 1605525
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
    Sternberg EM; Van Woert MH; Young SN; Magnussen I; Baker H; Gauthier S; Osterland CK
    N Engl J Med; 1980 Oct; 303(14):782-7. PubMed ID: 6997735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Sclerodermiform and poikilodermal syndrome observed during treatment with carbidopa and 5-hydroxytryptophan].
    Auffranc JC; Berbis P; Fabre JF; Garnier JP; Privat Y
    Ann Dermatol Venereol; 1985; 112(9):691-2. PubMed ID: 4091416
    [No Abstract]   [Full Text] [Related]  

  • 5. [Sclerodermiform and poikilodermic syndrome during treatment with carbidopa and 5-hydroxytryptophan. Culture of fibroblasts with biochemical analysis of collagen metabolism].
    Chamson A; Périer C; Frey J
    Ann Dermatol Venereol; 1986; 113(1):71. PubMed ID: 3486623
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug-related scleroderma-like illness. The Fine page.
    Fine RM
    Int J Dermatol; 1981 Jun; 20(5):354. PubMed ID: 6972361
    [No Abstract]   [Full Text] [Related]  

  • 7. An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan.
    Michelson D; Page SW; Casey R; Trucksess MW; Love LA; Milstien S; Wilson C; Massaquoi SG; Crofford LJ; Hallett M
    J Rheumatol; 1994 Dec; 21(12):2261-5. PubMed ID: 7699627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan.
    Klarskov K; Johnson KL; Benson LM; Gleich GJ; Naylor S
    Adv Exp Med Biol; 1999; 467():461-8. PubMed ID: 10721089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa.
    Van Woert MH; Rosenbaum D; Howieson J; Bowers MB
    N Engl J Med; 1977 Jan; 296(2):70-5. PubMed ID: 401457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-tryptophan-induced eosinophilia-myalgia syndrome. I. Report of two cases with pseudoxanthoma-elasticum-like skin changes.
    Mainetti C; Schmied E; Masouyé I; Chavaz P; Saurat JH
    Dermatologica; 1991; 183(1):57-61. PubMed ID: 1769422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxic oil syndrome (Spanish oil disease) and chemically induced scleroderma-like conditions.
    Rush PJ; Bell MJ; Fam AG
    J Rheumatol; 1984 Jun; 11(3):262-4. PubMed ID: 6204046
    [No Abstract]   [Full Text] [Related]  

  • 12. [L-5-hydroxytryptophan(L-5-HTP) therapy of Parkinson's disease. 2].
    Sano I; Taniguchi K
    Munch Med Wochenschr; 1972 Oct; 114(40):1717-9. PubMed ID: 4538893
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations.
    Thal LJ; Sharpless NS; Wolfson L; Katzman R
    Ann Neurol; 1980 Jun; 7(6):570-6. PubMed ID: 6969054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mianserin agranulocytosis followed by oxitriptan eosinophilia].
    García C
    Nervenarzt; 1992 May; 63(5):303-7. PubMed ID: 1603192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myoclonus and L-5-hydroxytryptophan (L-5HTP).
    Van Woert MH
    Prog Clin Biol Res; 1983; 127():43-52. PubMed ID: 6351100
    [No Abstract]   [Full Text] [Related]  

  • 16. l-5-Hydroxytryptophan in depression: the first substitution therapy in psychiatry? The treatment of 99 out-patients with 'therapy-resistant' depressions.
    van Hiele LJ
    Neuropsychobiology; 1980; 6(4):230-40. PubMed ID: 6967194
    [No Abstract]   [Full Text] [Related]  

  • 17. Structural characterization of a case-implicated contaminant, "Peak X," in commercial preparations of 5-hydroxytryptophan.
    Klarskov K; Johnson KL; Benson LM; Cragun JD; Gleich GJ; Wrona M; Jiang XR; Dryhurst G; Naylor S
    J Rheumatol; 2003 Jan; 30(1):89-95. PubMed ID: 12508395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of L-5-hydroxytryptophan in autistic children.
    Sverd J; Kupietz SS; Winsberg BG; Hurwic MJ; Becker L
    J Autism Child Schizophr; 1978 Jun; 8(2):171-80. PubMed ID: 307546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of L-5-hydroxytryptophan on self-mutilatin in Lesch-Nyhan disease: a negative report.
    Anderson LT; Herrmann L; Dancis J
    Neuropadiatrie; 1976 Nov; 7(4):439-42. PubMed ID: 1087383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin and myoclonus.
    Van Woert MH; Jutkowitz R; Rosenbaum D; Bowers MB
    Monogr Neural Sci; 1976; 3():71-80. PubMed ID: 790170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.